Quantcast

Tag Archives: neuralstem

Md. biopharm gets 2 new neurodegenerative disorder treatment patents

(pressmaster / Depositphotos.com)

Neuralstem Inc., a Germantown biopharmaceutical company working on treatments for nervous system diseases, was awarded two patents by the U.S. Patent and Trademark Office. One patent covers ways of treating neurodegenerative disorders through transplantation of neural stem cells. The other covers ...

Read More »

As stock falls, Md. biopharm aims to raise under $6m in stock offering

(kwanchaidp / Depositphotos.com)

Germantown-based Neuralstem Inc., a biopharmaceutical firm developing treatments for nervous system diseases on Thursday announced plans to raise less than $6 million through an underwritten public offering. Neuralstem will offer 3 million shares of common stock and warrants to purchase up to 2.25 ...

Read More »

Md. biopharm’s antidepressant has mixed results in clinical trial

(kwanchaidp / Depositphotos.com)

A Maryland biopharmaceutical company on Tuesday announced mixed results for its phase 2 clinical trial of its experimental antidepressant. The study, by Germantown-based Neuralstem Inc. of its NSI-189 drug, given once and twice daily to treat major depressive disorder, didn’t show ...

Read More »

Neuralstem posts bigger loss

Neuralstem, of Germantown, a biotechnology company that produces stem-cell treatments for central nervous system diseases and conditions, reported a bigger loss for 2014 than in 2013. Neuralstem posted a net loss of $22.6 million, or 26 cents per share, compared ...

Read More »

Neuralstem loss lower in quarter

Neuralstem Inc., a Germantown-based biotechnology company, narrowed its loss in the third quarter. Neuralstem reported a net loss of $4.5 million, or 5 cents per share, compared with $6.7 million, or 9 cents, for the same period in 2013. The ...

Read More »

Neuralstem Phase I trial starts in San Diego

Neuralstem Inc., of Germantown, a biotechnology company, announced that the first patient was treated last week in the Phase I trial testing its NSI-566 human neural stem cells for chronic spinal cord injury. The trial occurred at the UC San ...

Read More »

Rockville-based Neuralstem reports higher 2Q loss

Neuralstem Inc., of Rockville, a biotherapeutic company developing products to treat central nervous system disorders with patented stem cell technology, reported a second-quarter net loss of $6.25 million, or 9 cents per share, compared to a net loss of $2.5 million, or 4 cents per share, in the prior-year period.

Read More »